KLRS Stock — Kalaris Therapeutics Inc.: Cash, EV, Pipeline

Share price

$3.20

Market cap

$76.2M

Cash

$93.5M

Enterprise value

-$17.3M

Balance sheet

Cash	$93.5M
Debt	$0.0M
Net cash	$93.5M
Enterprise value	-$17.3M
Basic shares	23.8M shares
Fully diluted shares	28.3M shares
Fully diluted market cap	$90.6M
Cash per share	$3.93

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading KLRS daily closes…

Loading price history…

Pipeline assets

TH103

Phase 2 · Active

Target VEGF

Partnerships License to use technology (with right to sublicense) related to new anti-VEGF agents and novel long-acting VEGF inhibitors for intraocular neovascularization

Indications

Neovascular age-related macular degeneration (nAMD) (Phase 2)
Other exudative and neovascular retinal diseases (Stage not disclosed)

Catalysts

— first half of 2027
— year-end 2027

Status note Lead and only named product candidate; novel clinical-stage anti-VEGF drug engineered for extended intraocular retention with enhanced VEGF inhibition. Ongoing Phase 1b/2 trial in nAMD designed to identify optimal dose/regimen for Phase 3.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
RTW Investments	1,300,000	no change	0.05%	2026-08-14
Ikarian Capital	360,000	no change	0.24%	2026-08-14
ADAR1 Capital Management	100,000	no change	0.02%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

KLRS — Kalaris Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders